1-Ethylquinolonium

1-Ethylquinolonium

SCHEMBL4624855

CC[n+]1cccc2ccccc21.F[B-](F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 13/20 0.55
BCHE P06276 12/20 0.55
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
RGS12 O14924 1/20 0.53
NPC1 O15118 1/20 0.53
USP2 O75604 1/20 0.53
LMNA P02545 1/20 0.53
HSP90AA1 P07900 1/20 0.53
THRB P10828 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
RAD52 P43351 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
MCL1 Q07820 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1-Ethylquinolonium SCHEMBL309459 0.92 ACHE (0.63) ACHEBCHEKDM4EMEN1RGS12
1-Ethylquinolonium SCHEMBL30920082 0.90 KDM4E (0.62) ACHEBCHEKDM4EMEN1RGS12
1-Ethylquinolonium SCHEMBL18804795 0.90 ACHE (0.61) ACHEBCHEKDM4EMEN1RGS12
1-Ethylquinolonium SCHEMBL9135771 0.90 ACHE (0.62) ACHEBCHEKDM4EMEN1RGS12
1-Ethylquinolonium SCHEMBL186988 0.90 KDM4E (0.62) ACHEBCHEKDM4EMEN1RGS12
1-Ethylquinolonium SCHEMBL10655763 0.90 ACHE (0.64) ACHEBCHE
1-Ethylquinolonium SCHEMBL28221155 0.89 ACHE (0.55) ACHEBCHEKDM4EMEN1RGS12
1-Ethylquinolonium SCHEMBL9645182 0.84 ACHE (0.50) ACHEBCHEKDM4EMEN1RGS12
1-Ethylquinolonium SCHEMBL18321286 0.83 ACHE (0.46) ACHEBCHEKDM4EMEN1RGS12
1-Ethylquinolonium SCHEMBL29623615 0.83 ACHE (0.53) ACHEBCHEKDM4EMEN1RGS12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2022-03-29 US claimed
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-05-20 US claimed
WO-2018163217-A2 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2018-09-13 WO claimed
US-11926727-B2 Epoxy resin composition HUNTSMAN INTERNATIONAL LLC (US) 2024-03-12 US disclosed
US-20220135766-A1 Epoxy Resin Composition HUNTSMAN INTERNATIONAL LLC 2022-05-05 US disclosed
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2022-03-29 US disclosed
EP-3310838-B1 EPOXY RESIN COMPOSITION HUNTSMAN ADV MAT LICENSING SWITZERLAND GMBH (CH) 2021-08-18 EP disclosed
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2021-05-20 US disclosed
WO-2018163217-A2 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2018-09-13 WO disclosed
CN-108350150-A Composition epoxy resin 亨斯迈先进材料许可(瑞士)有限公司 2018-07-31 CN disclosed
US-20180171101-A1 Epoxy Resin Composition HUNTSMAN INTERNATIONAL LLC 2018-06-21 US disclosed
EP-3310838-A1 EPOXY RESIN COMPOSITION Huntsman Advanced Materials Licensing (Switzerland) GmbH (CH) 2018-04-25 EP disclosed
WO-2016202608-A1 EPOXY RESIN COMPOSITION HUNTSMAN ADVANCED MATERIALS (SWITZERLAND) GMBH (CH) 2016-12-22 WO disclosed
EP-1432388-B1 AGENT FOR COLOURING FIBRES CONTAINING KERATIN HENKEL AG & CO KGAA (DE) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11286240-B2 Catalyst bound alpha radical and synthesis of OXO compounds using the same CBR1, POR, CAT ACHE 941/4885BCHE 1349/4885KDM4E 3025/4885
US-20210147364-A1 A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME CBR1, POR, CAT ACHE 1023/4885BCHE 1674/4885KDM4E 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.